Anti-CD40 conditioning enhances the TCD8 response to a highly tolerogenic epitope and subsequent immunotherapy of simian virus 40 T antigen-induced pancreatic tumors

Journal of Immunology

Volumn 179, Issue 10, 2007, Pages 6686-6695

  Otahal, Pavel ^a,c   Knowles, Barbara B ^b   Tevethia, Satvir S ^a   Schell, Todd D ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b JACKSON LABORATORY   (United States)

^c INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD40 ANTIBODY; CD40 ANTIGEN; EPITOPE; INSULIN; UNCLASSIFIED DRUG; VIRUS T ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL LINEAGE; CELL SURVIVAL; CONTROLLED STUDY; EMBRYO; FEMALE; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INSULINOMA; KINETICS; MALE; MOUSE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; SIMIAN VIRUS 40; T LYMPHOCYTE; ADOPTIVE TRANSFER; ANIMAL; CELL TRANSFORMATION; GENETICS; IMMUNOLOGY; PATHOLOGY; PROMOTER REGION; RAT; TRANSGENIC MOUSE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CD8-POSITIVE T-LYMPHOCYTES; CELL TRANSFORMATION, NEOPLASTIC; EPITOPES, T-LYMPHOCYTE; IMMUNE TOLERANCE; MICE; MICE, TRANSGENIC; PANCREATIC NEOPLASMS; PROMOTER REGIONS (GENETICS); RATS;

EID: 38449121160     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.10.6686     Document Type: Article

References (67)

1. + T cell tolerance and cancer immunotherapy. J. Immunother. 26: 1-11.
2. Pardoll, D. 2003. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21: 807-839.
3. Boon, T., and P. van der Bruggen. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183: 725-729.
4. Gattinoni, L., D. J. Powell, Jr., S. A. Rosenberg, and N. P. Restifo. 2006. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6: 383-393.
5. + T cell effector function in SV40 T antigen transgenic mice. J. Immunol. 171: 697-707.
6. Staveley-O'Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95: 1178-1183.
7. + T cells. J. Exp. Med. 198: 569-580.
8. Schell, T. D., B. B. Knowles, and S. S. Tevethia. 2000. Sequential loss of cytotoxic T lymphocyte responses to simian virus 40 large T antigen epitopes in T antigen transgenic mice developing osteosarcomas. Cancer Res. 60: 3002-3012.
9. + T cells against an immunodominant epitope and promotes lifelong control of pancreatic tumor progression in SV40 tumor antigen transgenic mice. J. Immunol. 177: 3089-3099.
10. Heath, W. R., and F. R. Carbone. 2001. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19: 47-64.
11. Gajewski, T. F., Y. Meng, C. Blank, I. Brown, A. Kacha, J. Kline, and H. Harlin. 2006. Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev. 213: 131-145.
12. + T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med. 5: 780-787.
13. Diehl, L., A. T. den Boer, S. P. Schoenberger, E. I. van der Voort, T. N. Schumacher, C. J. Melief, R. Offringa, and R. E. Toes. 1999. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 5: 774-779.
14. Roth, E., J. Schwartzkopff, and H. Pircher. 2002. CD40 ligation in the presence of self-reactive CD8 T cells leads to severe immunopathology. J. Immunol. 168: 5124-5129.
15. Garza, K. M., S. M. Chan, R. Suri, L. T. Nguyen, B. Odermatt, S. P. Schoenberger, and P. S. Ohashi. 2000. Role of antigen-presenting cells in mediating tolerance and autoimmunity. J. Exp. Med. 191: 2021-2027.
16. Maxwell, J. R., J. D. Campbell, C. H. Kim, and A. T. Vella. 1999. CD40 activation boosts T cell immunity in vivo by enhancing T cell clonal expansion and delaying peripheral T cell deletion. J. Immunol. 162: 2024-2034.
17. Quezada, S. A., L. Z. Jarvinen, E. F. Lind, and R. J. Noelle. 2004. CD40/CD154 interactions at the interface of tolerance and immunity. Annu. Rev. Immunol. 22: 307-328.
18. Bennett, S. R., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. Miller, and W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478-480.
19. Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483.
20. + CTL to cause tumor eradication. J. Immunol. 173: 6753-6759.
21. - tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc. Natl. Acad. Sci. USA 99: 5561-5566.
22. Nguyen, L. T., A. R. Elford, K. Murakami, K. M. Garza, S. P. Schoenberger, B. Odermatt, D. E. Speiser, and P. S. Ohashi. 2002. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J. Exp. Med. 195: 423-435.
23. + cell responses. J. Immunol. 170: 2727-2733.
24. Hanahan, D. 1985. Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315: 115-122.
25. Ye, X., J. McCarrick, L. Jewett, and B. B. Knowles. 1994. Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice. Proc. Natl. Acad. Sci. USA 91: 3916-3920.
26. Tevethia, S. S., and T. D. Schell. 2002. The immune response to SV40, JCV and BKV. In Human Polyomaviruses: Molecular and Clinical Perspectives. K. Khalili, and G. L. Stoner, eds. Wiley-Liss, New York, pp. 585-610.
27. Mylin, L. M., R. H. Bonneau, J. D. Lippolis, and S. S. Tevethia. 1995. Hierarchy among multiple H-2b-restricted cytotoxic T lymphocyte epitopes within simian virus 40 T antigen. J. Virol. 69: 6665-6677.
28. + Tlymphocyte responses to multiple epitopes from simian virus 40 (SV40) large T antigen in C57BL/6 mice immunized with SV40, SV40 T-antigen-transformed cells, or vaccinia virus recombinants expressing full-length T antigen or epitope minigenes. J. Virol. 74: 6922-6934.
29. Tanaka, Y., R. W. Anderson, W. L. Maloy, and S. S. Tevethia. 1989. Localization of an immunorecessive epitope on SV40 T antigen by H-2Db-restricted cytotoxic T-lymphocyte clones and a synthetic peptide. Virology 171: 205-213.
30. + T-cell/ dendritic cell interactions in vivo. Cell. Immunol. 214: 110-122.
31. Pretell, J., R. S. Greenfield, and S. S. Tevethia. 1979. Biology of simian virus 40 (SV40) transplantation rejection antigen (TrAg): in vitro demonstration of SV40 TrAg in SV40 infected non-permissive mouse cells by the lymphocyte-mediated cytotoxicity assay. Virology 97: 32-41.
32. Rolink, A., F. Melchers, and J. Andersson. 1996. The SCID but not the RAG-2 gene product is required for Sμ-Sε heavy chain class switching. Immunity 5: 319-330.
33. Skinner, P. J., M. A. Daniels, C. S. Schmidt, S. C. Jameson, and A. T. Haase. 2000. Cutting edge: in situ tetramer staining of antigen-specific T cells in tissues. J. Immunol. 165: 613-617.
34. Cavender, J. F., A. Conn, M. Epler, H. Lacko, and M. J. Tevethia. 1995. Simian virus 40 large T antigen contains two independent activities that cooperate with a ras oncogene to transform rat embryo fibroblasts. J. Virol. 69: 923-934.
35. Hawiger, D., K. Inaba, Y. Dorsett, M. Guo, K. Mahnke, M. Rivera, J. V. Ravetch, R. M. Steinman, and M. C. Nussenzweig. 2001. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194: 769-779.
36. Garbi, N., B. Arnold, S. Gordon, G. J. Hammerling, and R. Ganss. 2004. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J. Immunol. 172: 5861-5869.
37. Ganss, R., E. Ryschich, E. Klar, B. Arnold, and G. J. Hammerling. 2002. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 62: 1462-1470.
38. Galon, J., A. Costes, F. Sanchez-Cabo, A. Kirilovsky, B. Mlecnik, C. Lagorce-Pages, M. Tosolini, M. Camus, A. Berger, P. Wind, et al. 2006. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964.
39. + tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum. Pathol. 35: 808-816.
40. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99: 16168-16173.
41. + T cells during negative selection results in an altered antiviral T cell hierarchy. J. Immunol. 170: 1231-1239.
42. Lippolis, J. D., L. M. Mylin, D. T. Simmons, and S. S. Tevethia. 1995. Functional analysis of amino acid residues encompassing and surrounding two neighboring H-2Db-restricted cytotoxic T-lymphocyte epitopes in simian virus 40 tumor antigen. J. Virol. 69: 3134-3146.
43. + T cell response to a subdominant tumor antigen epitope. J. Immunol. 175: 700-712.
44. Singh, S., S. R. Ross, M. Acena, D. A. Rowley, and H. Schreiber. 1992. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med. 175: 139-146.
45. Yu, P., D. A. Rowley, Y. X. Fu, and H. Schreiber. 2006. The role of stroma in immune recognition and destruction of well-established solid tumors. Curr. Opin. Immunol. 18: 226-231.
46. Elder, D. 1999. Tumor progression, early diagnosis and prognosis of melanoma. Acta Oncol. 38: 535-547.
47. Zhang, L., J. R. Conejo-Garcia, D. Katsaros, P. A. Gimotty, M. Massobrio, G. Regnani, A. Makrigiannakis, H. Gray, K. Schlienger, M. N. Liebman, et al. 2003. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348: 203-213.
48. Ibe, S., Z. Qin, T. Schuler, S. Preiss, and T. Blankenstein. 2001. Tumor rejection by disturbing tumor stroma cell interactions. J. Exp. Med. 194: 1549-1559.
49. Blankenstein, T. 2005. The role of tumor stroma in the interaction between tumor and immune system. Curr. Opin. Immunol. 17: 180-186.
50. Ochsenbein, A. F., S. Sierro, B. Odermatt, M. Pericin, U. Karrer, J. Hermans, S. Hemmi, H. Hengartner, and R. M. Zinkernagel. 2001. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411: 1058-1064.
51. Yu, P., Y. Lee, W. Liu, R. K. Chin, J. Wang, Y. Wang, A. Schietinger, M. Philip, H. Schreiber, and Y. X. Fu. 2004. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat. Immunol. 5: 141-149.
52. + T lymphocytes by the endogenous tumor antigen. J. Immunol. 167: 6947-6956.
53. Hollenbaugh, D., N. Mischel-Petty, C. P. Edwards, J. C. Simon, R. W. Denfeld, P. A. Kiener, and A. Aruffo. 1995. Expression of functional CD40 by vascular endothelial cells. J. Exp. Med. 182: 33-40.
54. Karmann, K., C. C. Hughes, J. Schechner, W. C. Fanslow, and J. S. Pober. 1995. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc. Natl. Acad. Sci. USA 92: 4342-4346.
55. Prilliman, K. R., E. E. Lemmens, G. Palioungas, T. G. Wolfe, J. P. Allison, A. H. Sharpe, and S. P. Schoenberger. 2002. Cutting edge: a crucial role for B7-CD28 in transmitting T help from APC to CTL. J. Immunol. 169: 4094-4097.
56. + T cells responding to self-antigens. J. Exp. Med. 196: 323-333.
57. Roth, E., and H. Pircher. 2004. IFN-γ promotes Fas ligand- and perforin-mediated liver cell destruction by cytotoxic CD8 T cells. J. Immunol. 172: 1588-1594.
58. Ye, X., A. Kralli, R. Ge, R. P. Ricciardi, and B. B. Knowles. 1994. Downregulation of MHC class I antigen in insulinoma cells controlled by the R1 element of the H-2 enhancer. Oncogene 9: 1195-1204.
59. Marton, I., S. E. Johnson, I. Damjanov, K. S. Currier, J. P. Sundberg, and B. B. Knowles. 2000. Expression and immune recognition of SV40 Tag in transgenic mice that develop metastatic osteosarcomas. Transgenic Res. 9: 115-125.
60. Keir, M. E., S. C. Liang, I. Guleria, Y. E. Latchman, A. Qipo, L. A. Albacker, M. Koulmanda, G. J. Freeman, M. H. Sayegh, and A. H. Sharpe. 2006. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203: 883-895.
61. + T cell tolerance to tissue antigens. J. Immunol. 177: 8291-8295.
62. + T cells in the absence of tumor-antigen vaccination. Proc. Natl. Acad. Sci. USA 98: 10811-10816.
63. + T cell expansion with variable dependence on type I IFN. J. Exp. Med. 199: 775-784.
64. + T cells. J. Immunol. 173: 2217-2221.
65. Montfort, M. J., H. G. Bouwer, C. R. Wagner, and D. J. Hinrichs. 2004. The development of functional CD8 T cell memory after Listeria monocytogenes infection is not dependent on CD40. J. Immunol. 173: 4084-4090.
66. Behrens, G. M., M. Li, G. M. Davey, J. Allison, R. A. Flavell, F. R. Carbone, and W. R. Heath. 2004. Helper requirements for generation of effector CTL to islet β cell antigens. J. Immunol. 172: 5420-5426.
67. + dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J. Exp. Med. 196: 1099-1104.